Takeaways from #AHA2024. Late breaking trials - take home points
@AHAScience
1. BPROAD Trial: Intensive treatment targeting SBP ≤120 mmHg reduced the incidence of MACE at 5 years vs. standard treatment targeting ≤140 mmHg in patients with type 2 diabetes and hypertension with elevated CV risk.
She asked a legit question, you could have answered it without derogatory remarks in light of religious teachings, that is condemning the act and calling out to hypocrites who exploit minors..
Tsk tsk tsk